In recent years, there have been several reviews on gut microbiota, obesity and cardiometabolism summarizing interventions that may impact the gut microbiota and have beneficial effects on the host (some examples include [1] [2] [3]). In this review we discuss how the gut microbiota changes with weight loss (WL) interventions in relation to clinical and dietary parameters. We also evaluate available evidence on the heterogeneity of response to these interventions. Two important questions were generated in this regard: 1) Can response to an intervention be predicted? 2) Could preintervention modifications to the gut microbiota optimize WL and metabolic improvement? Finally, we have delineated some recommendations for future research, such as the importance of assessment of diet and other environmental exposures in WL intervention studies, and the need to shift to more integrative approaches of data analysis.
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Rodent models
Studies in rodent models have shed light on the role that gut microbiota may be playing in obesity. It has been demonstrated in rodents that an obese phenotype can be transmitted via the microbiota. Gut microbiota, depending on its composition and function, may be involved in several mechanisms leading to fat mass gain and eventually obesity. Among the mechanism the role of energy harvest from food (shown to be more efficient in certain bacterial groups) has been proposed. Germ free mice are resistant to diet-induced obesity,[6,7] but gain weight upon transfer of gut microbiota from conventionally raised mice or ob/ob mice, potentially through increased capacity for energy harvest.
[8] Gut microbiota may also impact host metabolism in the development of rodent obesity through the induction of hepatic lipogenesis, and suppression of Fiaf in the gut epithelia, leading to upregulation of LPL activity and increased fat storage. [6] There is also a direct interaction between the gut microbiota, the gut-associated immune system, and adipose tissue through metabolic endotoxemia.[9-11] Therefore, other effects such as the regulation of lipogenesis and gluconeogenesis, gut hormone secretion and induction of inflammatory response have also been demonstrated in rodents. [5] In addition, rodent models have been used to investigate the relationship between genetics and gut microbiota, [12] and these studies have shown that different genetic backgrounds can lead to very diverse host-environment interactions.
Gut microbiota changes due to CR can be significant and depend on the type of intervention. For example, duration of CR can impact both gut microbiota composition and health outcomes. Zhang 
In humans
Divergence in human gut microbiota composition is associated to multiple factors.
Microbiota enterotypes have been defined in different populations around the world.
Differentiation into these enterotypes cannot be explained by individual factors such as age or degree of corpulence, geographical location, or by dietary modifications of short duration. [14] Instead, long-term dietary habits and certain clinical characteristics seem to be stronger determinants for these compositional differences. [15] Obese and non-obese subjects have a different gut microbial profile.[16-20] Ley et al. showed that obese subjects have lower Bacteroidetes to Firmicutes ratio than lean subjects.
[8] However, these findings have not been consistent in the literature. [21] Another study showed greater abundance in the Firmicutes group Eubacterium rectale / Clostridium coccoides in obese women with metabolic syndrome versus obese women with no metabolic complications and non-obese women. [19] There was a correlation between this bacterial group and certain clinical outcomes such as visceral adiposity.
These findings suggest a different energy harvesting potential, consistent with the capacity of Firmicutes species to degrade non-digestible polysaccharides, although this remain to be proven.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
An important aspect of gut microbial composition in relation to host health is microbial richness, referring to diversity in the gut ecosystem. Microbial richness is overall higher in lean vs. obese subjects, and this correlates with a healthier metabolic profile. [16, 22] However even in subjects with different corpulence (lean vs. obese), metagenomic sequencing has revealed that different patterns of low or high diversity exist. When considering abundance of individual species, higher abundance of certain species such as Faecalibacterium prausnitzii (F. prausnitzii) [16, 23, 24] and Akkermansia muciniphila (A. muciniphila) [25, 26] have been repeatedly associated with a healthier status.
In CR studies there have been some consistent shifts in microbial composition.
Interestingly, it appears that certain characteristics in the gut, together with diet, associate with individual response to CR and lifestyle interventions. Such baseline differences and varied outcomes have been identified in the MICRO-Obes study, where a population of 49 overweight and obese individuals has been thoroughly studied in terms of gut microbiota composition, clinical parameters, and dietary intake. It was first shown that these individuals could be clustered by their response profile to 6 weeks of CR followed by a 6 week weight stabilization period. There were baseline differences in clinical parameters and microbiota among the three WL response clusters. Namely, Lactobacillus/Leuconostoc/Pediococcus group, was most abundant at baseline in the cluster of worst responders to CR and WS. However, the response to the intervention could be better predicted by baseline insulin sensitivity and inflammatory parameters illustrating the fact that we need deeper insight into the predictive potential of gut microbiota in dietary intervention. [27] M A N U S C R I P T
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More recently, it was shown in both the MICRO-Obes and MetaHIT studies that individuals can be stratified by their microbial richness, and those with higher richness (about 60-80%) tend to have a healthier metabolic status [22] and dietary intake. [28] MICRO-Obes subjects that had higher baseline microbial richness tended to respond better to the dietary intervention in terms of blood lipids, insulin sensitivity and low-grade inflammation.
Finally, as it will be described in more detail in the following section, higher baseline A. muciniphila was associated with a healthier metabolic profile in the same study.
[26] Individuals with a higher baseline abundance of this species had better outcomes from the intervention, namely a greater reduction in waist circumference, blood lipids, and increase in insulin sensitivity. Individuals with higher A. muciniphila in the context of higher microbial richness were also the most metabolically healthy throughout the intervention, illustrating the importance to take into account the overall gut microbial ecosystem, rather than focusing solely on one species.
The functional capacity of the gut microbiota in CR can be studied through modelisation of metagenomic information and through direct measure of metabolites in fluids (metabolomics). In a randomized cross-over study comparing a 4-week high were found between good (>4 kg WL) and bad (<2 kg WL) responders to CR, and changes in certain bacterial groups were associated with WL or improvement in clinical outcomes ( Table 1) .
Given the intricate relationship between the gut microbiota and host, a key question is whether modification of gut microbiota before interventions through diet and/or prebiotic treatment (defined later in this review) has the potential to optimize WL and metabolic improvement. Studying baseline differences between responders and non-responders is key to answer this question (Figure 1) .
In conclusion, baseline profiles in microbiota and metabolic status, together dietary macronutrient intake, may play a role in outcomes from CR interventions. More detail is needed on the role of micronutrients. An interaction between diet and microbiota has been identified in the development of obesity in human-to-mouse microbial transplantation studies. 
Effects of prebiotic and probiotic on host metabolism: putative links with gut microbes
Numerous studies have demonstrated that manipulating the gut microbiota with dietary intervention (i.e., prebiotics and probiotics) may affect host metabolism (i.e., glucose, lipid and energy metabolism) (Figure 2) . In this section, we briefly discuss examples showing the impact of such intervention in preclinical models as well as recent evidence suggesting that dietary interventions using pre and probiotics may also be linked with gut microbes in humans.
Twenty years ago, Gibson and Roberfroid have developed the prebiotic concept, recently revised as "A non digestible compound that, through its metabolization by microorganisms in the gut, modulates composition and/or activity of the gut microbiota, thus conferring a beneficial physiological effect on the host". [36] Over the last decades, this concept has led to the investigation of key questions such as how changes in the gut microbiota induced by prebiotics but also specific bacteria contribute to regulate energy intake, fat mass development and glucose/lipid metabolism? We will first discuss data obtained in rodents and in the second part the effectiveness of such interventions on human health.
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Animal models
More than a decade ago, Cani et al. described that the three different prebiotics (i.e. inulin-type fructans, which varied according to their degree of polymerization (i.e., number of fructose moieties), differentially affected gut peptides secretion. They found that the administration of prebiotic compounds profoundly changes the gut microbiota composition and metabolic function contributing to the upregulation of two gut peptides involved in reduced food intake, namely Glucagon-like peptide-1 (GLP-1) and PYY, and a decreased plasma levels of the orexigenic peptide, ghrelin. [37, 38] By using culture and non-culture dependent tools it has been shown that the three prebiotics used were able to change the gut microbiota in favor of Bifidobacterium spp. The abundance of Bifidobacterium spp. was inversely associated with body weight, fat mass as well as metabolic endotoxemia and inflammation. [39] More recently, thanks to metagenomics tools, novel results have clearly shown that the modulation of the gut microbiota was more complex than a simple change in Bifidobacterium spp., indeed, dozens of taxa were changed upon prebiotic treatment in obese and diabetic rodents. [40] Among the taxa increased by the treatment, Akkermansia muciniphila was increased by about 100 fold. [40] Interestingly, the abundance of this bacteria was positively associated with a lower fat mass, an improved glucose tolerance and gut barrier function as well as with the number of intestinal L cells secreting GLP-1 and PYY. [40] Since this discovery, several studies have shown that the administration of Akkermansia muciniphila in obese and diabetic rodents reduces fat mass gain, insulin resistance, metabolic endotoxemia and low grade inflammation,[12, 41, 42] thereby showing that this bacteria may play a crucial role. Although the overall mechanisms are not fully elucidated, this bacterium reinforced the gut barrier function and contribute to regulate energy homeostasis. [41] M A N U S C R I P T
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Thus, taken together, a variety of rodent model studies indicate that prebiotics may elicit beneficial impacts in metabolic disorders associated with obesity and diabetes. Moreover, several studies indicate that some of these effects may be obtained with specific bacteria often misinterpreted as probiotic. Notably, the term probiotic is often misused (see the International Scientific Association for Probiotics and Prebiotics published a consensus statement clarifying the scope of and appropriate use for the term 'probiotic' (for a review, see [43] ).
Besides this important opinion, various strains of Lactobacillus and
Bifidobacterium have demonstrated beneficial effects, most of the time by maintaining glucose homeostasis and decreasing inflammation and hepatic steatosis. Importantly, some of these strains also affect body weight and fat mass development, whereas others do not (for comprehensive reviews on this topic). [44, 45] In summary, abundant literature have reported the impact of specific Lactobacillus or Bifidobacterium strains on obesity and associated disorders in rodents, however strains are not equally potent in terms of body weight and fat mass loss or improvement of glucose/lipid metabolism and inflammatory markers.
The following examples illustrate the concept that strains are not equipotent.
Lactobacillus gasseri BNR17 reduces body weight and fat mass in overweight rats, [46] whereas in diet-induced obese mice, Lactobacillus plantarum 14 reduces the mean adipocyte size and Lactobacillus paracasei F19 induces a reduction of total fat mass and plasma triglycerides. [47] Conversely, Lactobacillus acidophilus NCDC supplementation did not affect body fat mass and/or hepatic steatosis and muscle fat in obese mice. [48] Lactobacillus casei Shirota reduces insulin resistance and metabolic endotoxemia, without affecting fat mass and body weight in diet-induced obese mice. [49] Finally,
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Lactobacillus plantarum WCFS1 did not change body weight, fat mass or inflammation in diet-induced obese mice. [41] These examples clearly illustrate that although they are all Lactobacillus, specific strains are efficient on metabolic parameters whereas other not.
Similar to the Lactobacillus spp. examples, specific strains of Bifidobacterium have been shown to metabolic disorders in obese and diabetic models. [44] For example, a recent study has shown that Bifidobacterium pseudocatenulatum CECT 7765 reduces body weight gain, fat mass, plasma glucose and inflammation in in diet-induced obese mice. [50] In a similar model, Bifidobacterium longum supplementation has been found to reduce body weight gain, fat mass, insulin resistance, systolic blood pressure, and metabolic endotoxemia. [51] Another study demonstrated that supplementation with Bifidobacterium animalis subsp lactis 420 reduced inflammation and improved insulin in obese and diabetic mice. [52] Again, these selected examples also illustrate that Bifidobacterium strains may affect metabolism, not always by inducing a body weight loss but most likely by improving intestinal barrier.
In humans
A limited number of studies have evaluated whether effects observed in rodents can similarly be achieved in humans. Among these studies, the impact of fermentable carbohydrates (including prebiotics) feeding on enteroendocrine hormones such as GLP-1, PYY and ghrelin, the reduced plasma glucose and inflammatory tone has been generally replicated in both healthy or obese humans, [53] [54] [55] however, the impact on fat M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT mass and body weight remain limited. [56] Interestingly, in these studies the gut microbiota composition was not studies, except in Dewulf et al. 2013 , who shows that specific bacteria are positively and negatively correlated with fat mass, metabolic endotoxemia and glucose/lipid markers. [56] A study using synbiotic approaches that is a supplementation with prebiotics and probiotic (inulin-type fructans and Bifidobacterium longum) has shown in 66 overweight patients with non-alcoholic steatohepatitis a reduced steatosis, metabolic endotoxemia, insulin resistance, and inflammation. [57] Excluding these studies using prebiotic supplementation, only few studies have reported a beneficial impact of probiotics on obesity and type 2 diabetes in humans, with again a certain strain specificity (for review [58] ). More recently, similar to the results obtained in rodents, it has been shown that important variations of Akkermansia muciniphila quantity may be observed in the transfer from morbidly obese women, or women that had undergone either RYGB or vertical banded gastroplasty. [66] One unique feature of this study was that microbiota composition was studied long term, with fecal samples obtained 9 years after surgery, when the women were weight-stable. Changes in microbiota were not only maintained over time, they were also surgery-specific but independent of BMI. Even though the phenotype was transmitted from the two surgical groups to the mice, there were some functional and compositional differences in microbiota, such as higher Proteobacteria in the RYGB group, and lower abundance of E. rectale and Roseburia intestinalis in the sleeve group compared to the obese group. The fecal and circulating metabolite profiles were different between groups. This study provides compelling evidence of the role of microbiota in long term weight maintenance of bariatric patients.
The potential role of microbiota in human health improvement stemming from bariatric surgery has been recently summarized. [67, 68] As in mouse studies, the composition of gut microbiota in humans is extensively changed with bariatric surgery Bacteroidetes ratio, less butyrate fermentation, and more NEFA and bile acid secretion in the VSG group. [70] The authors argue that the decrease in proportion of Firmicutes would account for the decrease capacity to ferment SCFA, leading to less calorie extraction from diet and therefore greater benefit from the intervention. It is difficult to link this to clinical outcomes because the VSG group was heavier at baseline than the VLCD group.
Other bariatric interventions have included a small number of subjects. [71] [72] [73] Their design has been either cross-sectional, or with short-term follow-up ( Table 2) .
Some changes in gut microbiota have been consistent, such as a decrease in Firmicutes after surgery, increase Proteobacteria and a tendency towards an increase in Verrucomicrobia (Akkermansia).
Most importantly, very few bariatric intervention studies assessing microbiota have included dietary information and food intake behavior or other kinds of environmental exposures. Our group has recently reported that dietary quality in bariatric patients is poor, particularly protein intake. [74] In addition to change in food intake after M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT bariatric surgery, these subjects also receive protein supplementary that could impact on gut microbiota. Therefore, it will also be important to focus on dietary quality of bariatric patients before and after surgery to optimize response and increase the likelihood of a shift to a healthier gut microbiota.
Interpretation of microbial changes with human bariatric interventions need to be made with caution and with a thorough knowledge of the clinical background of the patients, as morbidly obese populations are usually taking multiple medications. The effect of polypharmacy, including metformin and other diabetes treatments, on the gut microbiota and its relation to health is only now being elucidated. [75, 76] 
INTEGRATION OF KNOWLEDGE AND POTENTIAL FOR FUTURE
Throughout this review we have discussed the interactions between three main elements: the host, the gut microbiota, and the environment. The advancement of available technologies for the assessment of gut microbiota is key in the work presented here. The field is shifting from targeted measurement of specific bacterial groups to a gut microbiota ecology approach. This is complementary to the thorough analysis of particular species of interest. With these advances in technology, microbiota will be more thoroughly characterized and quantified. This will include RNAseq and more detailed functional annotations. Other relevant measures include the gut environment, architecture and ecosystem, in conjunction with functional characteristics of the gut microbiota as a metabolic organ through the use of metabolomics.
From a clinical point of view, extensive phenotyping of populations is mandatory
to identify subgroups that may be responding differently to an intervention. Indeed, even if a population seems uniform in terms of BMI, there is non-negligible heterogeneity in M A N U S C R I P T
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body composition, which in turn would be associated with different profiles of metabolic health, as explained by Ahima and Lazar. [77] Clinical parameters, pathologies and other traits of the host must be studied in detail to identify subgroups that may respond differently to interventions.
Regarding the environment, there is a wide array of exposures influencing host and gut microbiota that are very difficult to measure. Diet is the factor with the greatest potential to influence the gut microbiota and, although it is often assessed, it is very difficult to measure it reliably. Dietary intake and habits should be routinely taken into consideration in the kinds of interventions we have covered in this review. At the same time, there are many other environmental factors that could be influencing microbiota, including drug intake, pollution and physical activity.
The gut microbiota is at the interphase between environment and host. It is important to study profiles from these three elements in parallel using data integration and systems biology approaches. [78, 79] This would allow a more profound understanding of the factors that may be influencing, or may be influenced, by gut microbiota, [80] as well as differentiation of individual subpopulations that may undergo different responses after a WL intervention (Figure 1) .
Ecosystem modelisation: a first step toward truly personalized nutrition?
An example of a potential approach for personalized improvement in metabolic Fecal and blood metabolomics analysis allowed validation of the relevance of this theoretical model. Actually subjects with lower microbial richness had a greater elevation of amino acids such as phenylalanine and branched chain amino acids (valine, leucine, isoleucine). Blood elevation of some of these amino acids has been linked to insulin resistance and also identified as risk factor for type 2 diabetes (e.g. phenylalanine). The dietary intervention led to a significant decrease of these metabolites together with increased gut microbiota richness. CASINO also modeled which specific bacterial groups contributed significantly to the production of these "deleterious" metabolites. 
